Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Manal F. Abdelmalek"'
Autor:
Rajanshu Verma, Naga Swetha Samji, Mary E. Rinella, Ashwani K. Singal, Aijaz Ahmed, Krishna C. Keri, David I. Bernstein, Manal F. Abdelmalek, Sanjaya K. Satapathy
Publikováno v:
Digestive Diseases and Sciences. 64:3413-3430
Nonalcoholic steatohepatitis is the fastest-growing indication for the liver transplant and a leading cause of hepatocellular carcinoma among patients listed for liver transplantation in the USA. Post-transplant nonalcoholic hepatic steatosis and ste
Autor:
Zachary Spiritos, Manal F. Abdelmalek
Publikováno v:
Transl Gastroenterol Hepatol
Metabolic syndrome is a major clinical disorder involving metabolic dysregulation characterized clinically with features of central obesity, insulin resistance (IR), type 2 diabetes, hypertension, and dyslipidemia. Metabolic syndrome is strongly asso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e61ff3d2418861dea40f49ad5acfb38
https://europepmc.org/articles/PMC7726307/
https://europepmc.org/articles/PMC7726307/
Autor:
Ying Wang, Cynthia D. Guy, Cynthia A. Moylan, Anna Mae Diehl, Catherine F. Howe, Manal F. Abdelmalek, Ricardo Henao, Kara Wegermann
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 5, Iss 4, Pp 608-617 (2021)
Hepatology Communications, Vol 5, Iss 4, Pp 608-617 (2021)
Identifying patients at higher risk for poor outcomes from nonalcoholic fatty liver disease (NAFLD) remains challenging. Metabolomics, the comprehensive measurement of small molecules in biological samples, has the potential to reveal novel noninvasi
Autor:
Zobair M. Younossi, Keith D. Lindor, Scott L. Friedman, Mary E. Rinella, Stephen H. Caldwell, Giulio Marchesini, Philippe Mathurin, Naga Chalasani, Rohit Loomba, Elisabetta Bugianesi, Brent A. Neuschwander-Tetri, Jacob George, Stephen A. Harrison, Lawrence Serfaty, Manal F. Abdelmalek, Zachary Goodman, Kathleen E. Corey, Arun J. Sanyal, Francesco Negro, Michael Charlton, Vlad Ratziu, Joel E. Lavine, Kris V. Kowdley, Quentin M. Anstee
Publikováno v:
Hepatology (Baltimore, Md.), vol 68, iss 1
Nonalcoholic fatty liver disease (NAFLD) and its progressive form non-alcoholic steatohepatitis (NASH), are rapidly becoming among the top causes of cirrhosis, hepatocellular carcinoma, and indications for liver transplantation. Other than lifestyle
Autor:
Reshma Shringarpure, Beatrice Ferguson, Brent A. Neuschwander-Tetri, Kris V. Kowdley, Rohit Loomba, Alexander Liberman, Arun J. Sanyal, Naga Chalasani, Norah A. Terrault, David Shapiro, Manal F. Abdelmalek, Lois Lee, Jianfen Chen, Arthur J. McCullough
Publikováno v:
Gastroenterology, vol 156, iss 1
Background & aimsNonalcoholic steatohepatitis (NASH) is a leading cause of liver transplantation, and many trials are underway to evaluate potential therapies. The farnesoid X receptor ligand obeticholic acid in the NASH treatment trial evaluated the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d18ec713126acb68c4a3666d57d25d50
https://escholarship.org/uc/item/19g5c7t3
https://escholarship.org/uc/item/19g5c7t3
Autor:
Ayako Suzuki, Cynthia D. Guy, Jagpal Singh Klair, Ju Dong Yang, Jeanne M. Clark, Katherine P. Yates, Anna Mae Diehl, Ryan M. Gill, Aynur Unalp-Arida, Manal F. Abdelmalek, Joel E. Lavine
Publikováno v:
Hepatology. 64:85-91
UNLABELLED Postmenopausal women with nonalcoholic steatohepatitis are at an increased risk of hepatic fibrosis compared with premenopausal women. Whether duration of estrogen deficiency in postmenopausal state dictates an individual's fibrosis risk r
Publikováno v:
Hepatology. 61:98-107
Hedgehog (Hh) ligand production by ballooned hepatocytes drives nonalcoholic steatohepatitis (NASH) progression in mice. The NIDDK-sponsored PIVENS trial (NCT00063622) showed that vitamin E (VitE) improved NASH. We investigated whether VitE treatment
Autor:
Manal F. Abdelmalek, Matthew R. Kappus
Publikováno v:
Clinics in liver disease. 21(2)
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developing countries. Approximately 25% of patients with NAFLD develop nonalcoholic steatohepatitis (NASH). NASH-related cirrhosis is now a leading listing
Autor:
Rosemarie Gagliardi, Goran B. Klintmalm, E. Steve Woodle, Kirti Shetty, Alan Norman Langnas, Manal F. Abdelmalek, Igal Kam, Andreas G. Tzakis, Darla K. Granger, Curtis Holt, Michael R. Lucey
Publikováno v:
ResearcherID
A retrospective chart review of 1065 consecutive liver allograft recipients in 11 centers from January 1997 to September 1998 was performed. Patients were followed for 3 years or until graft loss. Patients received either tacrolimus (n = 594), cyclos
Autor:
Gary L. Davis, Alan W. Hemming, Manal F. Abdelmalek, Consuelo Soldevila-Pico, David R. Nelson, Roberto J. Firpi, Chen Liu, James M. Crawford, Alan I. Reed
Publikováno v:
Liver Transplantation. 10:199-207
Recurrent hepatitis C infection is an important cause of progressive fibrosis, cirrhosis, and graft loss following orthotopic liver transplantation. Treatment for posttransplant recurrence of hepatitis C with interferon-based therapy is difficult but